Metrics for antibody therapeutics development

mAbs

Volumn 2, Issue 6, 2010, Pages 695-700

  Reichert, Janice M ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ADALIMUMAB; ALEMTUZUMAB; BASILIXIMAB; BELIMUMAB; BEVACIZUMAB; CANAKINUMAB; CERTOLIZUMAB PEGOL; CETUXIMAB; DACLIZUMAB; ECULIZUMAB; EFALIZUMAB; GEMTUZUMAB OZOGAMICIN; IBRITUMOMAB TIUXETAN; INFLIXIMAB; IPILIMUMAB; MONOCLONAL ANTIBODY; MOTAVIZUMAB; NATALIZUMAB; OKT 3; OMALIZUMAB; PALIVIZUMAB; PANITUMUMAB; RANIBIZUMAB; RITUXIMAB; TOCILIZUMAB; TOSITUMOMAB I 131; TRASTUZUMAB; UNINDEXED DRUG; USTEKINUMAB;

ACUTE GRAFT REJECTION; ASTHMA; B CELL LYMPHOMA; BIOENGINEERING; BREAST CANCER; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL RESEARCH; CLINICAL TRIAL; COLORECTAL CANCER; CROHN DISEASE; DRUG APPROVAL; DRUG DEVELOPMENT; DRUG SCREENING; HUMAN; KIDNEY GRAFT REJECTION; MULTIPLE SCLEROSIS; NONHODGKIN LYMPHOMA; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PSORIASIS; RESPIRATORY SYNCYTIAL VIRUS INFECTION; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; RHEUMATOID ARTHRITIS; UNITED STATES;

ANTIBODIES, MONOCLONAL; CLINICAL TRIALS AS TOPIC; DRUG DISCOVERY; HUMANS;

EID: 78649669018     PISSN: 19420862     EISSN: None     Source Type: Journal    
DOI: 10.4161/mabs.2.6.13603     Document Type: Review

References (14)

1. Reichert JM. Monoclonal antibodies as innovative therapeutics. Curr Pharma Biotechnol 2008; 9:423-30.
2. Reichert JM, Rosensweig CJ, Faden LB, Dewitz MC. Monoclonal antibody successes in the clinic. Nat Biotechnol 2005; 23:1073-8.
3. Reichert JM. Monoclonal antibodies in the clinic. Nat Biotechnol 2001; 19:819-22.
4. Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 2004; 3:711-6.
5. Veronese FM, Mero A. The impact of PEGylation on biological therapies. BioDrugs 2008; 22:315-29.
6. Cohen J, Wilson A. New challenges to medicare beneficiary access to mAbs. mAbs 2009; 1:56-66.
7. Nelson AL, Reichert JM. Development trends for therapeutic antibody fragments. Nat Biotechnol 2009; 27:331-7.
8. King DJ, Turner A, Farnsworth AP, Adair JR, Owens RJ, Pedley RB, et al. Improved tumor targeting with chemically cross-linked recombinant antibody fragments. Cancer Res 1994; 54:6176-85.
9. Hudson PJ, Souriau C. Engineered antibodies. Nat Med 2003; 9:129-34.
10. Sanz L, Cuesta AM, Compte M, Alvarez-Vallina L. Antibody engineering: facing new challenges in cancer therapy. Acta Pharmacol Sin 2005; 26:641-8.
11. Harmsen MM, De Haard HJ. Properties, production and applications of camelid single-domain antibody fragments. Appl Microbiol Biotechnol 2007; 77:13-22.
12. Saerens D, Ghassabeh GH, Muyldermans S. Single-domain antibodies as building blocks for novel therapeutics. Curr Opin Pharmacol 2008; 8:600-8.
13. Zider A, Drakeman DL. The future of monoclonal antibody technology. mAbs 2010; 2:361-4.
14. Nelson AL, Dhimolea E, Reichert JM. Development trends for human monoclonal antibody therapeutics. Nat Rev Drug Discov 2010;9:767-74